Digital health · Alcohol reduction
Reframe
A subscription app from Atlanta that helps people cut back on or quit drinking, built on habit change rather than treatment. It has no FDA record and no registered trial, and has since added a drinks line and a telehealth prescribing service.
An idea that changed targets twice
Two Georgia Tech undergraduates met in an introductory chemical process principles class and decided to build something. Their first target was hypoglycemia detection, dropped when they found a similar product already existed. Their second was obsessive compulsive disorder, which one of them lives with.
They took a prototype to doctors at Emory and Johns Hopkins, who told them the same distraction mechanism would fit alcohol better, and that the market was larger. The company was called Digital Sponsor then, after the human sponsors used in Alcoholics Anonymous. They renamed it once they decided the app was not only for people at the bottom.
The app shipped in the autumn of 2020. By April 2021 it had more than 3,000 paid subscribers, and by early 2022 the founders were telling reporters that annual recurring revenue had crossed $10 million.
The gap they aimed at
The pitch has been steady for five years. “If you’re drinking too much, you don’t have a lot of places to turn to for help,” Pradeep told InsideHook in 2025. Residential programmes are expensive; mutual aid groups carry stigma for some people. Reframe sells the space between them: daily lessons, a drink log, craving distractions, Zoom meetings and a forum.
That positioning is also a regulatory choice. Reframe is a consumer wellness subscription, not a regulated device and not a treatment programme. Its help pages say so plainly: “Please note, Reframe is not a detox or rehabilitation program. If you are in acute addiction, or experiencing symptoms of alcohol withdrawal you should seek medical attention immediately.” The terms behind its newer prescribing service go further, stating that “The Services are not intended for individuals who have been diagnosed with or are currently undergoing treatment for Alcohol Use Disorder (AUD) or any other alcohol-related diagnosis.”
The founders
Ziyi Gao took a bachelor’s in industrial engineering in 2017. Vedant Pradeep took degrees in chemical and computer engineering two years later. Neither has said he struggled with alcohol; Pradeep has said he uses the app’s tools for his own OCD compulsions.
What they had was a method. “We realized early on that we were out of our depth, but we drew strength from reaching out to experts in this space, talking to at least 500 people,” Gao told Georgia Tech in 2021. CREATE-X, the university accelerator, put in $20,000 in 2018. The pair ran on $120,000 of family and personal savings until a $1.4 million seed from Atlanta Ventures landed in early 2021. Y Combinator took them into the Summer 2021 batch, reportedly after rejecting them three times.
From app to pharmacy
The Series A closed as 2021 ended: $12.5 million led by Goodwater Capital at a $100 million post money valuation, with Atlanta Ventures, HOF Capital and Atlanta angels alongside. Then the product widened. In March 2025 Reframe launched Liquid Luck, a line of functional non alcoholic drinks. By 2026 it was running Reframe Med+, which pairs the app with a “compounded Naltrexone + B6” prescription.
That is the sharpest change in the company’s history, and Reframe is careful about where it sits. The Med+ terms state: “Reframe does not provide any medical services. Reframe is a technology company providing a technology platform.” The prescribing is done by “OpenLoop Health, Inc. and its affiliated medical groups”. The Med+ site tells prospective members the programme “is not intended to diagnose or treat alcohol use disorder” and points anyone who may need medical detox to SAMHSA or a healthcare provider.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Regulatory and research | No FDA 510(k) or PMA, no ClinicalTrials.gov registration, no NIH or NSF award for Reframe or Glucobit Inc. in searches run Sep 2026. The only public money on record is $20,000 of CREATE-X pre-seed funding in 2018. | Not found |
| Peer reviewed literature | No published study of the app in PubMed. It appears once in the literature, in a February 2025 Health Affairs Scholar study of app users, where it was the most commonly named app among 22 interviewees, used by 8. | Independent |
| Outcome claims | Company-reported and unaudited. The help pages state “91% of Reframe users report a substantial decrease in alcohol use within 3 months”. In 2022 the CEO told TechCrunch 88.63% of users “reported meeting their drinking goals” at two months. None has been externally reviewed. | Company-stated |
| Scientific backing | The company says the programme was built “Through our partners at Emory and Harvard University, and our Reframe scientific team”, naming no individuals. A 2024 review reported “its scientific board is comprised of doctors from Emory University”. Frank Spinelli, MD, is named as a medical advisor in a December 2025 release. | Company-stated |
| Who the coaches are | Not necessarily clinicians. Reframe’s own Thrive Coaching posting asks for “Certified Coaching credential(s) or licensure as a Mental Health Professional (LPC, LCSW, LMHC, or equivalent)”, so a certified coach with no licence qualifies. A 2026 review listed “Difficult to find background on coaches” among the drawbacks. | Company-stated |
| Prescribing | Reframe states it is not licensed to practise medicine and is not a pharmacy; Med+ clinicians come from OpenLoop Health, Inc. and its affiliated medical groups. | Company-stated |
| Consumer complaints | The Better Business Bureau profile, accessed Sep 18, 2026, is not accredited and records “9 total complaints in the last 3 years”, nearly all about billing: charges after a cancelled trial, duplicate coaching charges, an unauthorised $297 medication refill. Two are marked Unanswered. | Public record |
| Cancellation terms | The web terms require notice “at least thirty (30) days before such renewal” and state “payments are nonrefundable and there are no refunds or credits for partially used periods”. The Google Play listing says “Payment must be canceled at least 24 hours prior to renewal.” The Med+ terms require one day. | Terms disagree |
| Scale claims | The main site counted 3,120,987 downloads as of August 2025; Forbes put it near 2 million; in January 2026 the CEO said 5 million. Google Play shows 500K+, so most of the base is on iOS, but the company totals do not reconcile. | Claims differ |
Read plainly: Reframe has built a large paying consumer business on a behavioural product that no one outside the company has tested against a control group. Its numbers are engagement and self report, from people paying to succeed. That is not nothing, and the one independent study naming the app found it was the one users reached for most. It is not the evidence a regulator or a payer would accept, which is why the company does not ask them to.
What to watch
- Whether Med+ changes the regulatory posture. A compounded prescription sold beside a wellness app puts Reframe closer to telehealth rules, state prescribing law and pharmacy oversight than the app alone ever was.
- The billing record. The FTC Click to Cancel rule was vacated in July 2025, but the agency reopened the rulemaking on March 11, 2026 and keeps bringing subscription cases under ROSCA.
- Any published study, from a company sitting on what it calls the world’s largest repository of alcohol cessation data.
- A new Form D. Nothing since January 2022, while reported totals have risen to $24.7 million and $27 million.
In their words
“We realized early on that we were out of our depth, but we drew strength from reaching out to experts in this space, talking to at least 500 people.”
Ziyi Gao, co-founder, Georgia Tech College of Engineering, 2021 · Independent
“People want to be told what to do more than we expected.”
Vedant Pradeep, co-founder and CEO, Georgia Tech College of Engineering, 2021 · Independent
“For most people that are just looking to cut back, there’s really no solution.”
Vedant Pradeep, to Fortune, 2022 · Independent
“What it tells you is that the danger isn’t slipping, it’s giving up after you slip.”
Vedant Pradeep, to Hypepotamus, January 2026 · Independent
“you can’t determine an app’s success or potency by a company’s self-provided data”
Kirk Miller, InsideHook, January 2025 · Independent
“While there is limited assessment of their effectiveness”
Uscher-Pines and colleagues, on alcohol reduction apps as a category, Health Affairs Scholar, February 2025 · Peer reviewed
“The way they market this app is unethical and borderline predatory.”
Reviewer, Trustpilot page for reframeapp.com, accessed December 2025 · Consumer review
Related companies
Sources
- Public recordForm D, Glucobit Inc., CIK 0001905181
- Public recordFDA 510(k) and PMA searches, no results
- Public recordReframe BBB profile and complaint record, Atlanta
- Public recordReframe: Cut Back on Alcohol, developer Glucobit Inc.
- Peer reviewedThe role and reach of alcohol reduction apps
- IndependentEngineering Alumni Create Mobile App to Reduce Alcohol Abuse
- IndependentThe startup sobriety gambit
- IndependentApp to moderate drinking raises $12.5 million
- IndependentCan an App Help You Drink Less?
- IndependentReframe Dives Into Non-Alcoholic Beverages
- IndependentReframe Dry January data story
- Independent4 Apps To Help Drinkers Cut Back
- IndependentReframe App Review 2026
- IndependentVedant Pradeep, 30 Under 30 profile
- IndependentFTC Restarts Negative Option Rulemaking
- Consumer reviewTrustpilot review page for reframeapp.com
- CompanyReframe terms of use, about page and FAQ
- CompanyReframe Med+ site and terms
- CompanyRecovery Coach listing, Reframe Thrive Coaching
- CompanyReframe Dry and Damp January release
- CompanyReframe company page, Summer 2021 batch
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
